Fatty acids-carotenoid complex: An effective anti-TB agent from the chlorella growth factor-extracted spent biomass of Chlorella vulgaris

ConclusionThe study signifies the development of a potent therapeutic agent comprising of a complex of anti-TB agent (fatty acids) and antioxidants (carotenoids) from the CGF-extracted spent biomass of C. vulgaris.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research

Related Links:

Abstract Treating tuberculosis (TB) requires a multidrug course of treatment lasting 6 months, or longer for drug-resistant TB, which is difficult to complete and often not well tolerated. Treatment failure and recurrence after end-of-treatment can have devastating consequences, including progressive debilitation, death, the transmission of Mycobacterium tuberculosis - the infectious agent responsible for causing TB - to others, and may be associated with the development of drug-resistant TB. The burden on health systems is important, with severe economic consequences. Vaccines have the potential to serve as imm...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
AbstractThe discovery of drugs to treat tuberculosis (TB) was a major medical milestone in the twentieth century. However, from the outset, drug resistance was observed. Currently, of the 10 million people that exhibit TB symptoms each year, 450,000 have multidrug or extensively drug resistant (MDR or XDR) TB. While greater understanding of the host and pathogen (Mycobacterium tuberculosis, Mtb) coupled with scientific ingenuity will lead to new drugs and vaccines, in the meantime 4000 people die daily from TB. Thus, efforts to improve existing TB drugs should also be prioritized. Improved efficacy and decreased dose and a...
Source: Pharmaceutical Research - Category: Drugs & Pharmacology Source Type: research
The Global Report includes trends in TB incidence and mortality, data on case detection and treatment results for TB, multidrug-resistant TB, TB/HIV, and TB prevention. The report also includes an overview of pipelines for new TB diagnostics, drugs and vaccines.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
A 25 year-old tuberculosis patient is treated at her home in Funafuti, the main island of Tuvalu in the South Pacific. Credit: UNDP Tuvalu/Aurélia Rusek.By External SourceUNITED NATIONS, Oct 17 2019 (IPS) A staggering 1.5 million people died from tuberculosis (TB) last year, the UN health agency said on Thursday, in an appeal for far greater funding and political support to eradicate the curable and preventable disease. Caused by the bacteria Mycobacterium tuberculosis, TB commonly causes persistent coughing, fatigue and weight loss. According to the World Health Organization (WHO) and its latest Global TB Report, a...
Source: IPS Inter Press Service - Health - Category: International Medicine & Public Health Authors: Tags: Global Headlines Health Poverty & SDGs Source Type: news
Abstract Worldwide, tuberculosis (TB) is the leading cause of death due to infection with a single pathogenic agent, Mycobacterium tuberculosis In the absence of an effective vaccine, new, more powerful antibiotics are required to halt the growing spread of multidrug-resistant strains and to shorten the duration of TB treatment. However, assessing drug efficacy at the preclinical stage remains a long and fastidious procedure that delays progression of drugs down the pipeline and towards the clinic. In this investigation, we report the construction, optimization and characterization of genetically engineered near-i...
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research
CONCLUSION: Nanomedicine holds bright prospect to perform key role in global tuberculosis elimination program. PMID: 31218956 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
Most vaccines for diseases in low- and middle-income countries fail to be developed because of weak or absent market incentives. Conquering diseases such as tuberculosis, HIV, malaria, and Ebola, as well as illnesses caused by multidrug-resistant pathogens, requires considerable investment and a new sustainable model of vaccine development involving close collaborations between public and private sectors.
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Perspectives Source Type: research
Publication date: Available online 29 May 2019Source: Pharmacological ResearchAuthor(s): Bahman Khameneh, Milad Iranshahy, Nasser Vahdati-Mashhadian, Amirhossein Sahebkar, Bibi Sedigheh Fazly BazzazAbstractTuberculosis (TB) is currently a clinical and public health problem. There is a concern about the emergence and development of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) species. Additionally, the lack of effective vaccines is another limitation to control the related infections. To overcome these problems various approaches have been pursued such as finding novel drug candidates with a new mech...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Aims What is the evidence base for the effectiveness of interventions to reduce tuberculosis (TB) incidence in countries which have low TB incidence? Methods We conducted a systematic review of interventions for TB control and prevention relevant to low TB incidence settings (
Source: European Respiratory Review - Category: Respiratory Medicine Authors: Tags: Respiratory infections and tuberculosis Review Source Type: research
The widespread availability and use of modern synthetic therapeutic agents have led to a massive decline in ethnomedical therapies. However, these synthetic agents often possess toxicity leading to various adverse effects. For instance, anti-tubercular treatment (ATT) is toxic, lengthy, and severely impairs host immunity, resulting in posttreatment vulnerability to reinfection and reactivation of tuberculosis (TB). Incomplete ATT enhances the risk for the generation of multidrug- or extensively drug-resistant (MDR or XDR, respectively) variants of Mycobacterium tuberculosis (M. tb), the TB-causing microbe. Therefore, a new...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Immunology Source Type: research
More News: Carbohydrates | Chlorella | Drugs & Pharmacology | Lutein | Minerals | Multidrug Resistance | Study | Tuberculosis | Vaccines | Vitamins